Effects of recombinant human growth hormone on fat distribution in patients with human immunodeficiency virus-associated wasting.
In light of current interest in recombinant human growth hormone (GH) as a treatment for fat distribution abnormalities, we retrospectively evaluated regional changes in fat and lean body mass in a subset of subjects who participated in randomized, double-blind, placebo-controlled trials of GH for treatment of wasting. Treatment with a pharmacologic dose of GH (0.1 mg/kg/day) resulted in significant and sustained increases in lean body mass and losses of fat in both the trunk and appendicular regions.
Tai
Viva W
VW
Department of Medicine, University of California, San Francisco, USA.
Schambelan
Morris
M
Algren
Heather
H
Shayevich
Clara
C
Mulligan
Kathleen
K
D000328:Adult; D002986:Clinical Trials as Topic; D005223:Fats / Q000378:metabolism*; D005260:Female; D015658:HIV Infections / Q000150:complications*; D019382:Human Growth Hormone / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008659:Metabolic Diseases / Q000188:drug therapy* / Q000209:etiology; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D012189:Retrospective Studies
D005223:Fats; D011994:Recombinant Proteins; D019382:Human Growth Hormone